Article
Accelerate Development of New Oncology Therapies with FDA's Project FrontRunner
May 20, 2024

Project FrontRunner is a paradigm shift in regulatory guidance that is moving oncology drug development into earlier stages of disease. The expectations from oncology drug developers will be to adapt their trial design, using fewer single-arm studies and instead shifting focus to randomized control trials that focus on development earlier in the cancer treatment pathway. IQVIA is here to help you navigate the changing landscape and partner with you to bring novel therapies to cancer patients faster.

Related solutions

Contact Us